Compare DigitalOcean Holdings Inc (DOCN) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs Neurocrine Biosciences Inc — how do they compare? DigitalOcean Holdings Inc trades at $132.1 (market cap $14.57B), while Neurocrine Biosciences Inc trades at $142.45 (market cap $14.36B). The key difference: DigitalOcean Holdings Inc and Neurocrine Biosciences Inc are close in size by market cap, and DigitalOcean Holdings Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DigitalOcean Holdings Inc for 43 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DOCN | NBIX | |
|---|---|---|
Market Cap | $14.57B | $14.36B |
Volume | 2,261,786 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $181.29 | $185.50 |
52-Week Low | $37.30 | $123.10 |
Typical Hold Time | 43 Days | 23 Days |
Enterprise Value | $15.33B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean trades at $127.28, down 2.89% today, with strong fundamentals including 29% revenue growth and consistent earnings beats. The company shows robust profitability with 57.22% gross margins and 23.27% net income margin, though valuation metrics remain elevated with P/E of 56.32. Recent AI-focused product launches and $725 million equipment financing facility support growth initiatives. Technical indicators show mixed signals with bullish oscillators but bearish moving averages, trading near key support at $126.
Outlook remains positive with analyst consensus target of $172.73 (35.7% upside) and 68% buy ratings. Key opportunities include AI-driven revenue growth and expanding cloud market share, while risks include high valuation, negative shareholder equity, and competitive pressure from larger cloud providers. The stock offers growth potential but requires careful monitoring of execution and market conditions.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
